argenx SE (ARGX) News
Follow argenx SE (ARGX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 41 public stories across 26 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Argenx Agrees to Acquire Unnatural Products for Up to $1.15 Billion
Argenx will pay $550 million in cash upfront, with the total price reaching up to $1.15 billion. The acquisition brings Unnatural Products’ peptide-discovery technology in-house.
EQUITY | Nov 09, 2026, 06:42 AM UTC
M
Argenx to Buy Unnatural Products
MNA | Nov 09, 2026, 06:06 AM UTC
M
Argenx to acquire Unnatural Products
Argenx says the acquisition will add a peptide discovery engine and broaden its immunology capabilities.
EQUITY | Nov 09, 2026, 06:02 AM UTC
L
Form SCHEDULE 13G/A ARGENX SE Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:12 PM UTC
M
Argenx Q3 Profit Rises to $506 Million
Argenx reported third-quarter profit attributable to owners of $506 million, up from $344 million a year earlier.
EQUITY | Oct 22, 2026, 05:57 AM UTC
M
Argenx Says Vyvgart Sales Rose 54% in Third Quarter
Argenx said global sales of its Vyvgart autoimmune drug rose 54% in the third quarter.
EQUITY | Oct 22, 2026, 05:52 AM UTC
M
ARGX Reports ALKIVIA Phase 3 Success and Q3 Revenue of About $1.67B
EQUITY | Oct 20, 2026, 07:05 AM UTC
M
Argenx Expected to Post Earnings of $7.98 a Share
An earnings preview cites expected earnings of $7.98 per share.
EQUITY | Oct 20, 2026, 06:32 AM UTC
M
Argenx says Phase 3 ALKIVIA study met primary endpoint
EQUITY | Oct 19, 2026, 12:06 PM UTC
M
argenx to report third-quarter 2026 results on October 22
The company also plans a business update.
EQUITY | Oct 15, 2026, 05:00 AM UTC
H
Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 150 points on Thursday. The Dow traded down 0.39% to 50,978.59 while the NASDAQ declined 0.61% to 27,371.84. The S&P 500 also fell,
LIVE | Oct 08, 2026, 04:03 PM UTC
H
Argenx halts late-stage Sjogren’s trial of Vyvgart
Argenx stopped a late-stage clinical trial of Vyvgart for Sjogren's disease due to lack of efficacy, with shares down 18% in European morning trading.
EQUITY | Oct 08, 2026, 09:48 AM UTC
H
Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Applied Digital Corp (NASDAQ: APLD ) rose sharply in pre-market trading after the company posted better-than-expected financial results for the first quarter. Applied Digital reported first-quarter adjusted rev
LIVE | Oct 08, 2026, 08:32 AM UTC
L
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
September 29, 2026, 8:00 AM ESTAmsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, will present new data from across its portfolio and pipeline at the 2026 American A
NEWS | Sep 29, 2026, 12:02 PM UTC
L
These 'Moonshot' Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right. — Barrons.com
By Mackenzie TatananniFrom speculation over mergers and acquisitions to the hype surrounding clinical readouts, it seems biotechnology stocks are all the rage this year.The iShares Biotechnology exchange-traded fund has
NEWS | Sep 23, 2026, 05:45 AM UTC
L
ARGX cites Vision 2030 targets and immunology pipeline progress
Argenx says its Vision 2030 plan targets treating 50,000 patients and 10 diseases, citing strong progress in MG and CIDP and pipeline expansion.
EQUITY | Sep 08, 2026, 03:06 PM UTC
L
ARGX cites strong revenue growth and pipeline progress
ARGX says its Vision 2030 targets are advancing, with strong revenue growth and pipeline expansion via new indications and acquisitions. The company highlights VYVGART in MG and CIDP and adds empasiprubart and FB102 to d
EQUITY | Sep 08, 2026, 02:33 PM UTC
L
ARGX price target maintained at $1150 by Wedbush
Wedbush maintained its ARGX price target at $1150.00 per share by Wednesday, according to TradingView News/Benzinga.
EQUITY | Sep 08, 2026, 01:34 PM UTC
L
ARGX price target kept at $1,150 by Wedbush
Wedbush maintained a $1,150.00/share price target for ARGX, per Benzinga ratings actions.
EQUITY | Sep 03, 2026, 01:27 PM UTC
L
Argenx to present at upcoming investor conferences
Argenx plans to present at upcoming investor conferences.
EQUITY | Sep 01, 2026, 05:07 AM UTC
L
ARGX - argenx to Present at Upcoming Investor Conferences
ARGX - argenx to Present at Upcoming Investor Conferences
EQUITY | Sep 01, 2026, 05:00 AM UTC
L
argenx Is Maintained at Overweight by Morgan Stanley
argenx Is Maintained at Overweight by Morgan Stanley
EQUITY | Aug 31, 2026, 02:46 PM UTC
L
Weekly Recap: ALKIVIA Phase 3 VYVGART 52-week high and Forte adds FB102
Weekly Recap: ALKIVIA Phase 3 VYVGART 52-week high and Forte adds FB102
EQUITY | Aug 31, 2026, 05:14 AM UTC
L
News On Forte Biosciences Inc. (FBRX) Now Under ARGX.BT
News On Forte Biosciences Inc. (FBRX) Now Under ARGX.BT
EQUITY | Aug 27, 2026, 09:08 PM UTC
M
argenx completes acquisition of Forte Biosciences
argenx (ARGX) completed its acquisition of Forte Biosciences, Inc.
MNA | Aug 27, 2026, 12:52 PM UTC
L
Argenx price target raised by UBS
UBS raised its Argenx price target from $960.00 to a higher level, according to TradingView News.
EQUITY | Aug 26, 2026, 04:12 PM UTC
L
ARGX price target raised to $1,400 by UBS
UBS raised its Argenx target to $1,400 from $960, according to TradingView News.
EQUITY | Aug 26, 2026, 08:00 AM UTC
L
DBAB cuts Argenx to Hold on breather call
DBAB cuts ARGX Argenx to Hold, with the note saying it is time for a breather; no catalyst or magnitude was supplied.
EQUITY | Aug 24, 2026, 02:00 PM UTC
L
NY Empire State Manufacturing Index Rises to 20.6 in August
The New York Fed's Empire State Manufacturing Index surged to 20.6 in August from 15.6 in the prior month, topping market estimates of 11.
EARNINGS | Aug 17, 2026, 04:04 PM UTC
H
argenx reports positive Phase 3 ALKIVIA topline results
argenx (ARGX) announces positive topline results from its Phase 3 ALKIVIA trial of efgartigimod in autoimmune myositis.
EQUITY | Aug 17, 2026, 05:00 AM UTC
L
ARGX - argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
ARGX - argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
MNA | Aug 06, 2026, 11:48 AM UTC
L
argenx Sets Shareholder Meeting
argenx announces Extraordinary General Meeting
EQUITY | Aug 03, 2026, 08:01 PM UTC
L
FBRX downgraded to EW from Overweight after ARGX M&A headlines @ BARC
FBRX downgraded to EW from Overweight after ARGX M&A headlines @ BARC
MNA | Jul 28, 2026, 11:42 AM UTC
H
What You Missed On Wall Street On Monday
The major averages had a mixed day, with the Dow and the S&P 500 higher and Nasdaq in decline amid weakness in tech stocks as the market has reacted positively to easing geopolitical tensions and a steep decline in oil p
MACRO | Jul 27, 2026, 08:29 PM UTC
L
Forte Biosciences shares jump after $2.2 billion takeover agreement with argenx
Forte Biosciences shares jump after $2.2 billion takeover agreement with argenx
EQUITY | Jul 27, 2026, 11:10 AM UTC
H
earnings calendar: • earnings before the open: aal aci alle amal amp argx bfh bpop bx civb clf cmcsa coco cx dgx dov Dow fcnca fcx fsv hban
earnings calendar: • earnings before the open: aal aci alle amal amp argx bfh bpop bx civb clf cmcsa coco cx dgx dov Dow fcnca fcx fsv hban hog hon ibcp imax infy laz lmt mbly ndaq nok nsc nvcr orio pcg Pool r rop RTX sn
EARNINGS | Jul 23, 2026, 10:54 AM UTC
L
ARGX raise PT slightly to $1182 - IMNM is a high-PoS opportunity @ Citi
ARGX raise PT slightly to $1182 - IMNM is a high-PoS opportunity @ Citi
EQUITY | Jul 21, 2026, 10:41 AM UTC
L
argenx shares are trading higher after B of A Securities raised its price target from $1016 to $1088.
argenx shares are trading higher after B of A Securities raised its price target from $1016 to $1088.
EQUITY | Jul 02, 2026, 06:06 PM UTC
L
B of A Securities Maintains Buy on argenx, Raises Price Target to $1088
B of A Securities analyst Tazeen Ahmad maintains argenx (NASDAQ: ARGX ) with a Buy and raises the price target from $1016 to $1088.
EQUITY | Jul 02, 2026, 02:40 PM UTC
M
ARGX: H.C. Wainwright Remains Bullish
H.C. Wainwright remains bullish on Argenx despite changes to the Phase 3 Vyvgart study in myositis, citing strong prospects in immune-mediated necrotizing myopathy
EQUITY | Jun 25, 2026, 05:57 PM UTC
M
ARGX: HC Wainwright Maintains Buy
argenx shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and reiterated its $940 price target.
EQUITY | Jun 25, 2026, 02:04 PM UTC
M
Analysts Raise Targets
Top Wall Street analysts raise price targets for several stocks including Okta, International Seaways, and Ralliant
EQUITY | Jun 24, 2026, 01:00 PM UTC
M
ARGX: Morgan Stanley Raises PT
Morgan Stanley maintains overweight on argenx and raises price target to $1180
EQUITY | Jun 24, 2026, 12:52 PM UTC
M
Banks Initiate Coverage
Multiple banks initiate coverage on various stocks with different ratings
EQUITY | Jun 22, 2026, 10:57 AM UTC